Rahul Ballal Biography and Net Worth

Director of Enliven Therapeutics

Rahul is the Chief Executive Officer at Mediar Therapeutics and is a biopharmaceutical executive with more than 15 years of experience in business development, strategic transactions, and company financing. Rahul previously served as Imara’s (IMRA) president and chief executive officer. Prior to this role, he served as chief business officer of Northern Biologics and as an entrepreneur-in-residence at Versant Ventures. Previously, Dr. Ballal was vice president of business development at Flexion Therapeutics (FLXN). Additionally, Rahul currently serves on the Board of Directors of Agios (AGIO), and Vaderis Therapeutics AG.

Rahul holds a Ph.D. in biochemistry from Georgetown University, an M.S. in bioinformatics from Johns Hopkins University and a B.S. in biology from Brown University.

What is Rahul D. Ballal's net worth?: The estimated net worth of Rahul D. Ballal is at least $406,829.61 as of October 8th, 2024. Dr. Ballal owns 22,341 shares of Enliven Therapeutics stock worth more than $406,830 as of April 25th. This net worth approximation does not reflect any other investments that Dr. Ballal may own. Learn More about Rahul D. Ballal's net worth.
How do I contact Rahul D. Ballal?: The corporate mailing address for Dr. Ballal and other Enliven Therapeutics executives is 309 Beacon Street Suite 300 Office 341, Brookline MA, 02446. Enliven Therapeutics can also be reached via phone at 617-927-9989 and via email at ir@imaratx.com. Learn More on Rahul D. Ballal's contact information.
Has Rahul D. Ballal been buying or selling shares of Enliven Therapeutics?: Rahul D. Ballal has not been actively trading shares of Enliven Therapeutics in the last ninety days. Most recently, Rahul D. Ballal sold 10,420 shares of the business's stock in a transaction on Tuesday, October 8th. The shares were sold at an average price of $28.17, for a transaction totalling $293,531.40. Following the completion of the sale, the director now directly owns 22,341 shares of the company's stock, valued at $629,345.97. Learn More on Rahul D. Ballal's trading history.
Who are Enliven Therapeutics' active insiders?: Enliven Therapeutics' insider roster includes Rahul Ballal (Director), Rishi Gupta (Director), Richard Heyman (Chairman of the Board of Directors), Benjamin Hohl (Chief Financial Officer and Head of Corporate Development), Samuel Kintz (Co-founder, Chief Executive Officer, and Member of the Board of Directors), Joseph Lyssikatos (Co-founder, Chief Scientific Officer), and Anish Patel (Co-founder and Chief Operating Officer). Learn More on Enliven Therapeutics' active insiders.
Are insiders buying or selling shares of Enliven Therapeutics?: In the last twelve months, insiders at the sold shares 67 times. They sold a total of 1,443,876 shares worth more than $32,811,792.39. The most recent insider tranaction occured on April, 21st when insider Joseph P Lyssikatos sold 5,000 shares worth more than $80,350.00. Insiders at Enliven Therapeutics own 29.2% of the company. Learn More about insider trades at Enliven Therapeutics.
Information on this page was last updated on 4/21/2025.

Rahul D. Ballal Insider Trading History at Enliven Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/8/2024	Sell	10,420	$28.17	$293,531.40	22,341
4/11/2024	Sell	53,400	$23.95	$1,278,930.00	22,341
4/4/2024	Sell	3,485	$19.15	$66,737.75	22,341
4/1/2024	Sell	3,237	$19.08	$61,761.96	22,341

Rahul D. Ballal Buying and Selling Activity at Enliven Therapeutics

Enliven Therapeutics Company Overview

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Today's Range

Now: $18.21

$17.46

$18.40

50 Day Range

MA: $19.44

$14.91

$22.46

2 Week Range

Now: $18.21

$13.30

$30.03

Volume

124,974 shs

Average Volume

264,318 shs

Market Capitalization

$892.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.03